Homogeneous Polyporus Polysaccharide Inhibit Bladder Cancer by Resetting Tumor-Associated Macrophages Toward M1 Through NF-κB/NLRP3 Signaling

Bladder cancer(BC)is one of the most common urinary system tumors, which characterized by a high incidence. Polyporus polysaccharide is the main active component of polyporus, which is clinically used in the treatment of bladder cancer, but the mechanism is not clear. In previous study, we isolated...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 839460
Main Authors Liu, Chunping, He, Dongyue, Zhang, Shihui, Chen, Huiqi, Zhao, Jie, Li, Xiong, Zeng, Xing
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 04.05.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Bladder cancer(BC)is one of the most common urinary system tumors, which characterized by a high incidence. Polyporus polysaccharide is the main active component of polyporus, which is clinically used in the treatment of bladder cancer, but the mechanism is not clear. In previous study, we isolated homogeneous polyporus polysaccharide(HPP) with high purity from polyporus. The goal of this study was to assess the polarization of macrophages induced by HPP in the bladder tumor microenvironment and explored its anti-bladder cancer mechanism through BBN bladder cancer rat model and Tumor associated macrophages(TAM). The results suggested that HPP regulates TAM polarization to improve the tumor inflammatory microenvironment, possibly through the NF-κB/NLRP3 signaling pathway. Our results suggested that HPP may be a potential therapeutic agent for bladder tumors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Colin Dinney, University of Texas MD Anderson Cancer Center, United States; Wei Chen, Stanford University, United States; Shuai Wang, Xinxiang Medical University, China
Edited by: Sergei Kusmartsev, University of Florida, United States
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.839460